“Adverse pathology is a clear predictor of long-term outcomes for patients,” says Eric A. Klein, MD.
In this video, Eric A. Klein, MD, discusses the background and findings of the recent Urologic Oncology: Seminars and Original Investigations study, Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy, for which he served as senior author. Klein is the emeritus chair of the Cleveland Clinic Glickman Urological & Kidney Institute.
Grant to fund research on biomarkers for toxicity from prostate cancer radiation
July 11th 2024“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy," says Joanne B. Weidhaas, MD, PhD, MS.
Gene-expression signature could serve as biomarker for recurrence in ccRCC
June 26th 2024“Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer," says Simpa S. Salami, MD, MPH.